NASDAQ:BLRX BioLineRx - BLRX News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.76 +0.02 (+2.70%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.70▼$0.8050-Day Range$0.56▼$0.7452-Week Range$0.55▼$1.98Volume864,376 shsAverage Volume269,583 shsMarket Capitalization$46.76 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BLRX Media Mentions By Week BLRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLRX News Sentiment▼0.120.34▲Average Medical News Sentiment BLRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLRX Articles This Week▼31▲BLRX Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updatesfinance.yahoo.com - March 22 at 10:00 AMBioLineRx Ltd. (BLRX.TA)sg.finance.yahoo.com - March 20 at 2:46 PMStockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)americanbankingnews.com - March 20 at 6:28 AMBioLineRx to Report 2022 Annual Financial Results on March 22, 2023finance.yahoo.com - March 15 at 8:50 AMBioLineRx Ltd. (BLRX) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - March 12 at 7:05 AMBioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Diseasefinance.yahoo.com - March 6 at 10:04 AMBIOLINERX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firmbusinesswire.com - March 3 at 9:40 PMThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)businesswire.com - March 3 at 2:35 PMBioLineRx Ltd. (BLRX) Class Action Alert: Robbins LLP Urges Shareholders with Significant Losses in BioLineRx Ltd. to Contact the Firmbenzinga.com - January 27 at 8:43 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRXbenzinga.com - January 23 at 10:04 AMBronstein, Gewirtz & Grossman, LLC Notifies BioLineRx Ltd. (BLRX) Investors of Class Action and to Actively Participatebenzinga.com - January 17 at 12:12 AMBioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officerfinance.yahoo.com - January 4 at 10:36 AMBioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidatefinance.yahoo.com - December 28 at 10:23 AMBioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumorsfinance.yahoo.com - December 20 at 7:49 AMBLRX: Self-Commercialization in the USfinance.yahoo.com - December 5 at 2:56 PMBioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updatesfinance.yahoo.com - November 15 at 11:13 AMBioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilizationfinance.yahoo.com - November 10 at 8:14 PMBioLineRx to Report Third Quarter 2022 Results on November 15, 2022finance.yahoo.com - November 10 at 8:14 PMBioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notificationfinance.yahoo.com - November 4 at 5:45 PMBioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - November 3 at 11:02 AMBLRX: Cast Off the Bowlines: Aphexda Commercializationfinance.yahoo.com - November 2 at 7:58 PMBioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization - Yahoo Financefinance.yahoo.com - September 28 at 8:06 PMBioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilizationfinance.yahoo.com - September 27 at 7:48 AMForm 6-K BioLineRx Ltd. For: Sep 21 - StreetInsider.comstreetinsider.com - September 21 at 4:10 PMINVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100000 to Contact the Firm - Business Wirebusinesswire.com - September 20 at 7:45 PMBioLineRx Announces $15 Million Registered Direct Offering - Yahoo Financefinance.yahoo.com - September 19 at 5:55 PMEQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX - Business Wirebusinesswire.com - September 19 at 5:55 PMBioLineRx stock slips on $15M securities offering - Seeking Alphaseekingalpha.com - September 19 at 12:54 PMBioLineRx Announces $15 Million Registered Direct Offeringfinance.yahoo.com - September 19 at 12:53 PMBioLineRx (BLRX) Enters $40M Non-Dilutive Debt Financing Agreement with Kreos Capital - StreetInsider.comstreetinsider.com - September 15 at 8:51 PMBioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancerfinance.yahoo.com - September 15 at 3:50 PMBioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capitalfinance.yahoo.com - September 15 at 10:49 AMNew Therapeutics Options in Pancreatic Ductal Adenocarcinoma Pipeline as 40+ Key Companies are Working on Drug Profiles | DelveInsight - Yahoo Financefinance.yahoo.com - September 14 at 2:45 PMBioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization - Yahoo Financefinance.yahoo.com - September 14 at 3:31 AMBioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixa - Benzingabenzinga.com - September 13 at 5:30 PMBioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission Of New Drug Application To FDA For Motixafortid - Benzingabenzinga.com - September 12 at 6:31 PMBioLineRx Announces Submission Of Its First NDA - Quick Factsnasdaq.com - September 12 at 1:31 PMBioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilizationfinance.yahoo.com - September 12 at 7:58 AMGlobal Actinic Keratosis Treatment Market to Reach $10.08 Billion by 2027 at a CAGR of 10.61% - Yahoo Financefinance.yahoo.com - September 2 at 3:34 PMBLRX: September NDA - Benzingabenzinga.com - August 23 at 4:07 PMBLRX: September NDAfinance.yahoo.com - August 18 at 1:27 PMBioLineRx falls 9% as costs increase in second quarter - Seeking Alphaseekingalpha.com - August 17 at 5:25 PMBioLineRx Tops Q2 EPS by 12c By Investing.com - Investing.cominvesting.com - August 16 at 4:22 PMBioLineRx Tops Q2 EPS by 12c By Investing.com - Investing.com UKuk.investing.com - August 16 at 11:21 AMbiolinerx GAAP EPS of -$0.01 beats by $0.08 (NASDAQ:BLRX) - Seeking Alphaseekingalpha.com - August 16 at 11:21 AMBioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 16 at 11:21 AMBioLineRx to Report Second Quarter 2022 Results on August 16, 2022 - Benzingabenzinga.com - August 11 at 5:04 PMPositive Data from the Clinical Phase I MAD Study with AlzeCure's Alzheimer's Pproject NeuroRestore ACD856 - Yahoo Financefinance.yahoo.com - June 30 at 8:40 PMEvofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO - Yahoo Financefinance.yahoo.com - June 30 at 10:39 AMADRs End Lower; BioLineRx, Can-Fite BioPharma Trade Actively - Morningstarmorningstar.com - June 29 at 11:45 PM Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:BLRX) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.